Outcomes Based on the Pre-operative Integrity of IS/OS Junction in Idiopathic Epimacular Membrane Surgery

November 12, 2019 updated by: Carlo Bruttini, IRCCS Policlinico S. Matteo

Surgery for Idiopathic Epimacular Membrane: Morpho-functional Outcomes Based on the Pre-operative Macular Integrity of Photoreceptoral Junction. A Prospective Pilot Study.

The aim of this study is to evaluate whether the pre-operative integrity or not of the inner segment (IS) and outer segment (OS) photoreceptoral junction may influence the post-operative visual acuity, the macular morphology (assessed by Spectral Domain-Optical Coherence Tomography (SD-OCT)) and function (evaluated by Multifocal Electroretinogram -mfERG) in patients with idiopathic epimacular membrane (EMM) followed-up for 6-month.

In this observational prospective study, EMM patients are enrolled. They are divided into 2 groups in relationship to the pre-operative integrity of the SD-OCT IS/OS junction: the group with an intact IS/OS junction (EMM-I Group) and the group with a disrupted IS/OS junction (EMM-D Group). For each enrolled patient, visual acuity (VA), mfERG and SD-OCT were assessed at baseline (pre-operative) and after 1, 3 and 6 months of follow-up after surgical treatment for EMM (pars plana vitrectomy with EMM removal and internal limiting membrane peeling).

Study Overview

Detailed Description

In this observational study, patients with idiopathic EMM, undergoing pars plana vitrectomy with Inner Limiting Membrane (ILM) peeling, at the Ophtalmology Clinic of IRCCS Policlinico San Matteo, are enrolled.

The clinical diagnosis of EMM is based on indirect binocular ophthalmoscopy with a + 90 D no-contact lens (Volk Optical Inc., Ohio, USA) and on the SD-OCT examination (see below) which revealed an increase in macular volume associated with optically hyperreflective epiretinal echoes due to the presence of a membrane.

Since several pathologies may induce changes of the macula bioelectrical responses, and their presence may represent potential confounding factors, patients enrolled in the present study were selected from a large EMM cohort of patients after exclusion of presence of dense lens opacities, ocular hypertension or glaucoma, diabetic retinopathy, drusen and age-related macular disease, other general diseases such as systemic hypertension, diabetes, connective tissue or neurological diseases.

Based on that reported by Falkner-Radler et al. , our patient are divided into 2 groups in relationship to the integrity of IS/OS junction: a group in which an intact IS/OS junction was identified by SD-OCT examination (EMM-I Group) and a group in which a disrupted IS/OS junction was observed by SD-OCT examination, EMM-D Group.

Evaluation of photoreceptor status is performed on the central part of the 1.5 mm of two perpendicular scans centered on the fovea. The intact IS/OS junction is identified as a continuous hyperreflective line ; the disrupted IS/OS junction is identified as interruptions of the normal hyperreflective line. Classification was assessed by the agreement of two different grader. In case of disagreement a third assessment was obtained by another expert grader.

VA, mfERG and SD-OCT were assessed in each enrolled patient at baseline (pre-operative) and after 1, 3 and 6 month of follow-up after surgical treatment for EMM in each enrolled patient.

Surgical treatment

All the patients undergo a 25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted Epiretinal Membrane/Inner Limiting Membrane (ERM/ILM) removal performed by a single surgeon (GV); no air-fluid exchange is performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.

Visual acuity evaluation

Best-corrected VA is assessed by the modified ETDRS Charts (Lighthouse, Low vision products, Long Island City, N.Y. USA) and expressed in LogMAR values obtained at the distance of 4, 2, 1 and 0.5 meters.

MfERG recordings

The Espion D310 Profile Multifocal System (Diagnosis UK LTD, Histon, Cambridge, UK) is used to record the mfERG.

In all eyes, mfERGs are binocularly recorded under photopic conditions in normal room illumination. Pupils are maximally pharmacologically dilated with 1% tropicamide to a diameter of 7-8 mm. Binocular mfERG recording is preferred for helping subjects to have a stable target fixation. At every mfERG examination, each patient positively reported that he/she could clearly perceive the cross fixation target. The eye's position is continuously monitored by a fixation camera to track patient gaze.

The cornea is anesthetized with 0.4% oxybuprocaine. MfERGs are recorded bipolarly between an active electrode (Dawson-Trick-Litzkow -DTL- thread electrodes) and a reference Ag/AgCl electrode placed on the temple. A small Ag/AgCl skin ground electrode s placed at the center of the forehead. Interelectrode resistance is less than 5 KOhms.

The multifocal achromatic stimulus, consisting of 61 scaled hexagons, is displayed on a high-resolution liquid crystal displays (LCD), black-and-white 32" (diagonal) monitor (size 70 cm width and 39.5 cm height) with a frame rate of 75 Hz (base period for stimulus presentation is 13.3 ms). The hexagon-shaped stimuli are arranged along several concentric rings and are randomly alternated between black (1 cd/m2) and white (400 cd/m2), with the on-off string of each hexagon determined according to a 14-bit M-sequence. This resulted in a contrast of 99%. The luminance of the monitor screen is 200 cd/m2 and a central fixation red cross is used as target in the center of the stimulation field. The eccentricity of the outermost ring of the 61-hexagon array is about 30° (radius from the fixation point to edge of display).

The m-sequence had 213-1 elements and total recording time is approximately 5 min. Total recording time is divided into 9 segments, with a duration of 30 seconds each. Between segments, the subject is allowed to rest for a few seconds.

The signal is amplified (gain 100.000) and filtered (band pass 10-100 Hz) by LPC2000 Flash Utility software V2.2.1. After automatic rejection of artefacts (and blinks) and application of line current (50 or 60 Hz) interference filter (or Runtime Mains Rejection), and automatic rejection of the bioelectrical responses with noise greater than 1 μV root mean square (RMS), the system software (V6.58.2) provided the 1st order kernel response, that was normalized considering the ratio between the bioelectrical responses and the relative retinal area from which the signals were collected. In the 1st order kernel response, different peaks (called with the letter indicating the negative, N and positive, P polarity and the sequential number of appearance) are identified in a time after the 0 ms corresponding to the presentation of the visual stimuli.

In the analysis of normalized mfERG responses, the investigator considered the peak-to-peak amplitude between N1 and P1 peaks, called response amplitude density (RAD) measured in nanoVolt/degree2 (ɳV/deg2).

MfERG ring analysis is selected to differentiate changes of the bioelectrical responses of the foveal region with respect to the more eccentric macular areas. The investigators analyze the averaged response obtained from two concentric annular retinal regions (rings, R) centered on the fovea. Therefore, the investigators analyze the N1-P1 RADs derived from 0 to 5° (R1) and from 5 to 10° (R2).

SD-OCT assessment

All patients undergo structural SD-OCT scan using Heidelberg Spectralis (version 1.10.4.0, Heidelberg Engineering, Heidelberg Germany) after pupil dilation. The SD-OCT imaging protocol consist of at least 20°x15° volume scans of the macula area with 19 B-scans.

A qualitative analysis is performed in order to evaluate the integrity of the inner segment and outer segment photoreceptoral junction . Quantitative analysis of central retinal thickness (CRT), including the overall, the inner (I-CRT) and outer (O-CRT) CRT, and macular volume (MV) are automatically obtained from the macular map centered to the fovea, through an inbuilt software of Heidelberg Spectralis (version 1.10.2.0).

The research follows the tenets of the Declaration of Helsinki. Each patient signed an informed consent. The study was performed according to our routine clinical practice, thus IRB approval was not required.

Statistical Analysis

The Anderson-Darling and Kolmogorov-Smirnovtests are applied to verify that data were normally distributed. Only one eye is chosen for each patient.

Pearson's correlation is used to assess the relationship between the differences (logarithmic values at 1, 3 and 6 months minus logarithmic values at baseline) in VA and mfERG and SD-OCT data. All statistical analyses is performed using SPSS V.26 (Statistical Package for Social Science IBM), and a p-value less than 0.05 is considered as statistically significant.

Study Type

Observational

Enrollment (Actual)

18

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • MI
      • Milan, MI, Italy, 20133
        • Carlo Bruttini

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with idiopathic EMM, undergoing pars plana vitrectomy with ILM peeling, at the Ophtalmology Clinic of IRCCS Policlinico San Matteo

Description

Inclusion Criteria:

  • patients with idiopathic epimacular membrane

Exclusion Criteria:

  • presence of dense lens opacities, ocular hypertension or glaucoma, diabetic retinopathy, drusen and age-related macular disease, other general diseases such as systemic hypertension, diabetes, connective tissue or neurological diseases.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
EMM-I
Group with an intact IS/OS junction
25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
EMM-D
Group with a disrupted IS/OS junction
25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Imortance of the pre-operative integrity or not of the inner segment (IS) and outer segment (OS) photoreceptoral junction in the change of the post-operative visual acuity after 1, 3 and 6 months of follow-up after surgical treatment for EMM
Time Frame: 6 months
Visual acuity (VA)was assessed at baseline (pre-operative) and after 1, 3 and 6 months of follow-up after surgical treatment for EMM (pars plana vitrectomy with EMM removal and internal limiting membrane peeling
6 months
Importance of the pre-operative integrity or not of the inner segment (IS) and outer segment (OS) photoreceptoral junction in the change of the post-operative macular morphology after 1, 3 and 6 months of follow-up after surgical treatment for EMM
Time Frame: 6 months
SD-OCT (assessing macular morphology) was assessed at baseline (pre-operative) and after 1, 3 and 6 months of follow-up after surgical treatment for EMM (pars plana vitrectomy with EMM removal and internal limiting membrane peeling
6 months
Importance of the pre-operative integrity or not of the inner segment (IS) and outer segment (OS) photoreceptoral junction in the change of the post-operative macular function after 1, 3 and 6 months of follow-up after surgical treatment for EMM
Time Frame: 6 months
mfERG (assessing macular function) was assessed at baseline (pre-operative) and after 1, 3 and 6 months of follow-up after surgical treatment for EMM (pars plana vitrectomy with EMM removal and internal limiting membrane peeling
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Luciano Quaranta, Professor, IRCCS Policlinico San Matteo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 25, 2018

Primary Completion (Actual)

February 15, 2019

Study Completion (Actual)

July 9, 2019

Study Registration Dates

First Submitted

October 31, 2019

First Submitted That Met QC Criteria

November 6, 2019

First Posted (Actual)

November 12, 2019

Study Record Updates

Last Update Posted (Actual)

November 13, 2019

Last Update Submitted That Met QC Criteria

November 12, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SIEM28O219

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epimacular Membrane

Clinical Trials on pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling

3
Subscribe